Seres Therapeutics Reports Third Quarter 2026 Financial Results and Announces Plans for Advancing Development of SER-155 To Prevent Immune Checkpoint Inhibitor-Related Enterocolitis (irEC)
Key Highlights
- ➤SER-155 prevention study design expected for FDA submission in Q1 2027
- ➤12 of 15 moderate-to-severe irEC participants achieved immunosuppressive-free response
- ➤Seres reported $16.3 million third-quarter net loss versus $8.2 million income
- ➤Seres held $17.5 million cash at September 30; runway extends through Q1 2027
- ➤Nestlé paid Seres a second $12.5 million VOWST milestone installment in October
Expert Statements
Richard Kender, Executive Chairman and Interim Chief Executive Officer of Seres Therapeutics
“The irEC IST provided promising evidence that orally administered SER-155 improved epithelial barrier integrity and reduced gastrointestinal inflammation without systemic immunosuppression and was well-tolerated in patients with ICI-induced enterocolitis.”
Richard Kender, Executive Chairman and Interim Chief Executive Officer of Seres Therapeutics
“Based on those results, and in consultation with key opinion leaders in the field, we determined that developing SER-155 to prevent irEC could address a significant unmet clinical need in patients being treated with ICIs for their cancer.”
Richard Kender, Executive Chairman and Interim Chief Executive Officer of Seres Therapeutics
“We believe SER-155 may enable ICI patients, of whom there are currently estimated to be approximately 300,000 in the U.S. alone, to remain on their therapy by reducing the occurrence of irEC, which often requires the halting of life-saving cancer treatment.”
Richard Kender, Executive Chairman and Interim Chief Executive Officer of Seres Therapeutics
“We also think this development approach offers a time and capital efficient path to clinical data and positions SER-155 to potentially address a broad ICI-treated population and look forward to submitting our planned study design to the FDA in the first quarter of 2027.”
Richard Kender, Executive Chairman and Interim Chief Executive Officer of Seres Therapeutics
“We are pleased to have two oncology-focused programs for SER-155, one with the goal of preventing irEC, and the other, in allogeneic hematopoietic stem cell transplant (allo-HCT), aimed at reducing the risk of bloodstream infections, a leading cause of mortality in these patients.”
Richard Kender, Executive Chairman and Interim Chief Executive Officer of Seres Therapeutics
“We continue to seek capital through partnerships and other sources to advance our programs in irEC and in allo-HCT, which is Phase 2 ready, pending funding.”
Prevention approach aims to keep patients on immune checkpoint inhibitor (ICI) therapy and avoid immunosuppressive irEC treatments, representing an additional broad therapeutic opportunity for SER-155
Seres expects to submit plans for the next irEC study design to the FDA in Q1 2027
Get started
Create a free account to read the full story.